Table 2.
General characteristics of study participants at baseline
| Placebo group (n = 26) |
Alpha-lipoic acid group (n = 25) |
P1 | |
|---|---|---|---|
| Age (y) | 62.2 ± 10.1 | 66.1 ± 9.1 | 0.15 |
| Gender | |||
| Female | 12 (46.2%) | 14 (56.0%) | |
| Male | 14 (53.8%) | 11 (44.0%) | 0.57† |
| Height (m) | 159.1 ± 7.0 | 157.3 ± 9.3 | 0.44 |
| Weight-baseline (kg) | 69.7 ± 9.4 | 71.1 ± 10.9 | 0.63 |
| Weight at the end of trial (kg) | 69.5 ± 9.5 | 70.7 ± 10.6 | 0.68 |
| Body weight change (kg) | -0.2 ± 0.7 | -0.4 ± 1.4 | 0.55 |
| BMI- baseline (kg/m2) | 27.6 ± 3.5 | 28.8 ± 4.3 | 0.27 |
| BMI at the end of trial (kg/m2) | 27.5 ± 3.6 | 28.6 ± 4.1 | 0.29 |
| BMI change (kg/m2) | -0.1 ± 0.3 | -0.2 ± 0.6 | 0.47 |
| MET-h/day at study baseline | 25.1 ± 1.6 | 24.78 ± 1.6 | 0.42 |
| MET-h/day at end-of-trial | 25.3 ± 1.6 | 24.81 ± 1.6 | 0.31 |
| MET-h/day change | 0.1 ± 0.3 | 0.03 ± 0.3 | 0.31 |
Data are means ± SDs. METs, metabolic equivalents
1 Obtained from independent samples t-test
† Obtained from Fisher’s exact test